Der erste aus USA hat schon reagiert, Flaten hebt sein Kursziel um über 25% an
Biofrontera price target raised to $24 from $19 at Lake Street
Lake Street analyst Thomas Flaten raised his price target for Biofrontera to $24 from $19 saying the company's fiscal Q4 results and 2019 guidance underscore its success at driving penetration and adoption of Ameluz. The analyst affirms his Buy rating on the shares.
https://thefly.com/landingPageNews.php?id=2899954&headline=B…